News
2023.11.24
▲DXVX CEO Kwon Kyu-chan (right) and Dt&CRO Chairman Park Chae-gyu are taking photos.
DX&VX announced on the 24th that it has signed a strategic partnership with DT&CRO to begin pioneering the companion diagnostic market in earnest.
Kwon Kyu-chan, CEO of Dx&Vx, Lee Kyu-hang, Director of New Drug Research, Park Chae-gyu, President of DT&CRO, and Choi Soo-young attended the partnership signing ceremony held at DT&CRO in Yongin.
Through this strategic partnership, the two companies plan to cooperate on ™ non-clinical trials and clinical trials for the development of concomitant diagnosis, expanding the network of hospitals and hospitals, providing culture cell maintenance and immune cell profiling services, and providing concomitant diagnosis.
Accompanied diagnosis is a diagnostic technique that checks in advance whether a particular drug is effective for patients. When joint diagnosis is applied to new drug development, the success rate of new drug development is tripled and the cost of development is reduced by a third.
Dx&Vx will start its companion diagnosis business in earnest under the service name 'CLIDEX™'. CLIDEX stands for Cli-D-eX (Clinical Data Expert Program), meaning that it puts value on increasing the probability of clinical success for customers.
DT&CRO is a domestic full-service CRO that provides non-clinical and clinical trials in various areas such as pharmaceuticals, medical devices, food, chemicals, and cosmetics, and has been increasing the company's competitiveness since it was listed on the KOSDAQ in November last year. Synergy between the two companies is expected to be high in that they develop biomarkers needed in clinical practice at the preclinical stage.
An official from both companies said, "Through this strategic partnership, we will cooperate to provide high-quality services to companies that need companion diagnostic technology and to reduce the cost and duration of developing targeted anticancer drugs."
In addition to companion diagnostic services, Dx&Vx provides stem cell therapy and cancer cell line characteristics, genomic and immunodiagnostic analysis services to confirm genome instability, and immune cell profiling services through sequencing of immune cell receptors.
Source：etoday